文献速递前列腺癌

精细分析前列腺特异性抗原动力学预测前列腺癌主动监测结局

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
PubMed 文献 · Eur Urol · 2018-02-09

基于多中心Canary主动监测研究851例男性数据,采用线性混合效应模型计算PSA动力学参数,并分析其与活检再分类的关联。中位随访3.7年,255例(30%)发生再分类;校正前列腺体积、诊断时间、活检参数及诊断时PSA后,PSA动力学仍显著预测再分类(每增加0.10,HR=1.6,95%CI 1.2-2.1,p<0.001)。每6个月与每3个月检测PSA的模型性能基本一致。

要点

  • PSA动力学参数可独立预测主动监测中的活检再分类风险。
  • 重复PSA测量模型优于仅用诊断时PSA的模型。
  • 每6个月检测PSA与每3个月检测的模型性能基本一致。

核心结论

  • 基于线性混合效应模型计算的PSA动力学可显著预测活检再分类,重复PSA测量模型优于仅用诊断时PSA的模型。

研究设计与样本

  • 多中心Canary前列腺主动监测研究队列,纳入851例符合标准男性,按预定方案检测PSA并活检;采用线性混合效应模型构建PSA动力学参数,用多变量Cox比例风险模型评估与再分类的关联。

主要发现

  • 851例中255例(30%)在5年内发生再分类事件,中位随访3.7年。
  • 校正前列腺体积、诊断时间、活检参数及诊断时PSA后,PSA动力学每增加0.10的再分类风险比为1.6(95%CI 1.2-2.1,p<0.001)。
  • PSA动力学模型改善了风险预测最高和最低十分位组的风险分层。
  • 每6个月检测PSA与每3个月检测的模型性能基本一致。

临床怎么用

  • 可将基于线性混合效应模型的PSA动力学纳入主动监测方案和风险计算器,以辅助预测活检再分类风险。
  • 每6个月检测PSA的模型性能与每3个月检测基本一致,可考虑减少检测频率。

局限性

  • 再分类作为终点指标的可靠性是主要局限性,尽管其驱动多数治疗决策。
  • 结果需外部验证后方可用于指导主动监测方案和风险计算器。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For men on active surveillance for prostate cancer, utility of prostate-specific antigen (PSA) kinetics (PSAk) in predicting pathologic reclassification remains controversial. OBJECTIVE: To develop prediction methods for utilizing serial PSA and evaluate frequency of collection. DESIGN, SETTING, AND PARTICIPANTS: Data were collected from men enrolled in the multicenter Canary Prostate Active Surveillance Study, for whom PSA data were measured and biopsies performed on prespecified schedules. We developed a PSAk parameter based on a linear mixed-effect model (LMEM) that accounted for serial PSA levels. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association of diagnostic PSA and/or PSAk with time to reclassification (increase in cancer grade and/or volume) was evaluated using multivariable Cox proportional hazards models. RESULTS AND LIMITATIONS: A total of 851 men met the study criteria; 255 (30%) had a reclassification event within 5 yr. Median follow-up was 3.7 yr. After adjusting for prostate size, time since diagnosis, biopsy parameters, and diagnostic PSA, PSAk was a significant predictor of reclassification (hazard ratio for each 0.10 increase in PSAk=1.6 [95% confidence interval 1.2-2.1, p<0.001]). The PSAk model improved stratification of risk prediction for the top and bottom deciles of risk over a model without PSAk. Model performance was essentially identical using PSA data measured every 6 mo to those measured every 3 mo. The major limitation is the reliability of reclassification as an end point, although it drives most treatment decisions. CONCLUSIONS: PSAk calculated using an LMEM statistically significantly predicts biopsy reclassification. Models that use repeat PSA measurements outperform a model incorporating only diagnostic PSA. Model performance is similar using PSA assessed every 3 or 6 mo. If validated, these results should inform optimal incorporation of PSA trends into active surveillance protocols and risk calculators. PATIENT SUMMARY: In this report, we looked at whether repeat prostate-specific antigen (PSA) measurements, or PSA kinetics, improve prediction of biopsy outcomes in men using active surveillance to manage localized prostate cancer. We found that in a large multicenter active surveillance cohort, PSA kinetics improves the prediction of surveillance biopsy outcome.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Cooperberg MR, Brooks JD, Faino AV, et al. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018. PMID: 29433975. doi:10.1016/j.eururo.2018.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。